Woodstock Corp Trims Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Woodstock Corp reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,655 shares of the biopharmaceutical company’s stock after selling 505 shares during the period. Woodstock Corp’s holdings in Regeneron Pharmaceuticals were worth $3,316,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of REGN. Adirondack Trust Co. lifted its stake in shares of Regeneron Pharmaceuticals by 2.4% in the 3rd quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock valued at $453,000 after purchasing an additional 10 shares during the period. UMB Bank n.a. raised its holdings in Regeneron Pharmaceuticals by 1.1% in the third quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock worth $955,000 after purchasing an additional 10 shares in the last quarter. Trust Co. of Vermont lifted its position in Regeneron Pharmaceuticals by 8.3% during the third quarter. Trust Co. of Vermont now owns 157 shares of the biopharmaceutical company’s stock valued at $165,000 after buying an additional 12 shares during the period. Brighton Jones LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 1.5% during the 2nd quarter. Brighton Jones LLC now owns 920 shares of the biopharmaceutical company’s stock valued at $967,000 after buying an additional 14 shares in the last quarter. Finally, Nvwm LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 1.4% during the 3rd quarter. Nvwm LLC now owns 988 shares of the biopharmaceutical company’s stock valued at $1,039,000 after buying an additional 14 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $693.23 on Friday. The stock has a market capitalization of $76.18 billion, a price-to-earnings ratio of 17.15, a PEG ratio of 1.60 and a beta of 0.10. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The business’s fifty day moving average price is $744.16 and its 200-day moving average price is $954.41. Regeneron Pharmaceuticals, Inc. has a 1-year low of $666.25 and a 1-year high of $1,211.20.

Wall Street Analyst Weigh In

REGN has been the subject of a number of recent research reports. Morgan Stanley lowered their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Evercore ISI lowered their target price on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Citigroup cut their price target on Regeneron Pharmaceuticals from $895.00 to $795.00 and set a “neutral” rating on the stock in a research note on Tuesday. Truist Financial lowered their price objective on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research note on Wednesday, January 8th. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. One analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $1,015.38.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.